OTCMKTS:RSPI RespireRx Pharmaceuticals (RSPI) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free RSPI Stock Alerts $0.0009 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.0009▼$0.000950-Day Range N/A52-Week Range$0.0006▼$0.0191Volume420,000 shsAverage Volume12.12 million shsMarket Capitalization$673,973.34P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get RespireRx Pharmaceuticals alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About RespireRx Pharmaceuticals Stock (OTCMKTS:RSPI)RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.Read More RSPI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RSPI Stock News HeadlinesApril 20, 2024 | seekingalpha.comRCKT Rocket Pharmaceuticals, Inc.March 20, 2024 | globenewswire.comRespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord InjuryApril 26, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 9, 2024 | proactiveinvestors.comRespireRx Pharmaceuticals shares Preclinical Pain Relief for their Non-Opioid Lead KRM-II-81January 22, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of DirectorsJanuary 4, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic PatientDecember 11, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business DevelopmentOctober 12, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturingApril 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.October 12, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related ServicesAugust 30, 2023 | proactiveinvestors.comPharmaceutical cannabis sales surge, clinical trials seeing broader disease focusAugust 9, 2023 | benzinga.comRespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRxAugust 9, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating CompanyJune 24, 2023 | fool.comAlnylam Pharmaceuticals (NASDAQ: ALNY)May 24, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investmentMay 24, 2023 | finance.yahoo.comResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development CostsMay 16, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. (RSPI)April 21, 2023 | finance.yahoo.comRespireRx collaborates with University College London to study treatment options for GRIA disordersApril 20, 2023 | proactiveinvestors.comRespireRx collaborating with University College London to study treatment options for GRIA disordersApril 5, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA DisordersApril 3, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publicationsApril 3, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.March 28, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its boardMarch 28, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of DirectorsMarch 21, 2023 | seekingalpha.comRSPI RespireRx Pharmaceuticals Inc.March 2, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals subsidiary ResolutionRX signs on iNGENu as CRO for dronabinol developmentMarch 1, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals' Australian subsidiary ResolutionRx enters services agreement with CRO iNGENuSee More Headlines Receive RSPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RespireRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/19/2020Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:RSPI CUSIPN/A CIK849636 Webwww.respirerx.com Phone(201) 444-4947Fax949-727-3657Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,100,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,950.04% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-0.01Miscellaneous Outstanding Shares774,682,000Free Float387,109,000Market Cap$673,973.34 OptionableNot Optionable Beta0.49 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Arnold S. Lippa Ph.D. (Age 77)Executive Chairman, Interim President, Interim CEO & Chief Scientific Officer Comp: $339.6kDr. Jeff Eliot Margolis (Age 68)Senior VP, CFO, Treasurer, Secretary & Director Comp: $321.6kMr. Richard D. Purcell (Age 63)Senior Vice President of Research & Development Comp: $199.86kMr. David Dickason (Age 60)Senior Vice President of Pre-Clinical Product Development Mr. Marc M. RadinControllerKey CompetitorsAcura PharmaceuticalsOTCMKTS:ACURArgos TherapeuticsOTCMKTS:ARGSQAditxtNASDAQ:ADTXBellerophon TherapeuticsNASDAQ:BLPHChina SXT PharmaceuticalsNASDAQ:SXTCView All Competitors RSPI Stock Analysis - Frequently Asked Questions How have RSPI shares performed in 2024? RespireRx Pharmaceuticals' stock was trading at $0.0009 at the beginning of 2024. Since then, RSPI stock has decreased by 3.3% and is now trading at $0.0009. View the best growth stocks for 2024 here. Are investors shorting RespireRx Pharmaceuticals? RespireRx Pharmaceuticals saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 22,000 shares, a decrease of 73.1% from the March 31st total of 81,700 shares. Based on an average trading volume of 7,859,600 shares, the short-interest ratio is presently 0.0 days. View RespireRx Pharmaceuticals' Short Interest. How were RespireRx Pharmaceuticals' earnings last quarter? RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) issued its earnings results on Wednesday, August, 19th. The company reported ($0.01) earnings per share for the quarter. What other stocks do shareholders of RespireRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RespireRx Pharmaceuticals investors own include American Bio Medica (ABMC), Ballard Power Systems (BLDP), Alibaba Group (BABA), Arrowhead Pharmaceuticals (ARWR), Aquestive Therapeutics (AQST), Appian (APPN), Arista Networks (ANET), Alexion Pharmaceuticals (ALXN), Allergan (AGN) and Adamis Pharmaceuticals (ADMP). How do I buy shares of RespireRx Pharmaceuticals? Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RSPI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RespireRx Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
